Early demonstration of the potential efficacy of MYC inhibition came with the development of OmoMYC, an artificial MYC dominant-negative protein that effectively halts MYC-dependent transcription and leads to arrest and death in a wide variety of cancers [154,155,156,157]. Here, MYC is linked to cancer.